## Jonathon L Payne

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1384976/publications.pdf

Version: 2024-02-01

1162367 1281420 11 248 8 11 citations h-index g-index papers 11 11 11 542 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia. Leukemia, 2021, 35, 1267-1278.	3.3	10
2	Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children—a novel health disparity. Leukemia, 2021, 35, 2399-2402.	3.3	19
3	Cellular signaling and epigenetic regulation of gene expression in leukemia. Advances in Biological Regulation, 2020, 75, 100665.	1.4	20
4	Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2020, 21, 1718.	1.8	4
5	Transcriptional Regulation of Genes by Ikaros Tumor Suppressor in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 2020, 21, 1377.	1.8	8
6	IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia. Blood, 2020, 136, 1520-1534.	0.6	28
7	lkaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity. Leukemia, 2019, 33, 2720-2731.	3.3	32
8	Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros. Advances in Biological Regulation, 2017, 63, 71-80.	1.4	33
9	lkaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia. Oncotarget, 2017, 8, 8022-8034.	0.8	27
10	Casein kinase II (CK2) as a therapeutic target for hematological malignancies. Current Pharmaceutical Design, 2016, 22, 1-1.	0.9	37
11	Regulator of myeloid differentiation and function: The secret life of Ikaros. World Journal of Biological Chemistry, 2011, 2, 119.	1.7	30